Trial reportJournal of nephrology2024
First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting.
Trial report in Journal of nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05348733 (FINE-REAL), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Finerenone in IgA nephropathy: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States.Journal of clinical & translational endocrinology · 2026Article
- Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease.Diabetes, obesity & metabolism · 2026Review
- Pillar or poison? Evaluating overdose and safety challenges in newer diabetic kidney disease medications.Clinical kidney journal · 2026Article
- The appropriateness of finerenone initiation, dosing, and outcomes in diabetic kidney disease: data from real world practice.BMC nephrology · 2026Article
- Addressing unmet needs for chronic kidney disease treatment in type 1 diabetes: A review.Diabetes, obesity & metabolism · 2026Review
- From Evidence to Action: Advancing Timely Implementation of Triple Therapy in Type 2 Diabetes Mellitus and CKD.Kidney international reports · 2026Review
- Efficacy and Safety of Finerenone in Kidney Transplant Patients.Journal of clinical medicine · 2025Article
- Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study.Clinical kidney journal · 2025Article
- Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists.Reviews in cardiovascular medicine · 2025Review
- The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?Biomolecules · 2025Review
- The burden of hyperkalaemia in chronic kidney disease: a systematic literature review.Clinical kidney journal · 2025Article
- Efficacy and safety of add-on treatment with finerenone in patients with diabetic kidney disease already treated with SGLT-2 inhibitors.Clinical nephrology · 2025Article
- Article
- A Primary Care Guide to the Screening and Pharmacologic Management of Chronic Kidney Disease in People Living With Type 2 Diabetes.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Cost-effectiveness of treatment with finerenone in mild to advanced stage chronic kidney disease patients with type 2 diabetes from a societal perspective.BMJ public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundFinerenone, a selective non-steroidal mineralocorticoid receptor antagonist, improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The FINE-REAL study (NCT05348733) aims to evaluate the characteristics and treatment patterns of participants treated with finerenone in clinical practice.
methodsFINE-REAL is a prospective, single-arm, non-interventional study of patients initiated on finerenone as part of their routine care in accordance with country-approved labels. The study, initiated in June 2022, is expected to be completed by January 2028. The cutoff for this pre-specified interim analysis was June 13, 2023.
resultsParticipants were recruited across nephrology, endocrinology, cardiology, and primary care settings. Of 556 participants enrolled in the study by the cut-off date, 504 were included in this analysis (median follow-up duration of 7 months [finerenone treatment initiation to last recorded observation]). At baseline, 76.1% of participants were in the high or very high (KDIGO) CKD risk categories. Angiotensin converting enzyme inhibitors/angiotensin receptor blockers and sodium-glucose cotransporter 2 inhibitors were prescribed to 71.8% and 46.6% of participants, respectively. Based on prescribing information, 87.9% and 12.1% of participants initiated finerenone at doses of 10 and 20 mg, respectively. Finerenone treatment was uninterrupted in 92.3% of participants after 7 months' median follow-up. Treatment-emergent adverse events occurred in 110 (21.8%) participants. Hyperkalemia occurred in 25 (5.0%) participants, with no cases leading to death, dialysis, or hospitalization.
conclusionAt this interim analysis, finerenone was initiated in patients with CKD and T2D across various clinical practices participating in the study. Treatment discontinuation and hyperkalemia occurred infrequently.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.